Study on Clinical Curative Effects of Hoisting Soup in the Treatment of Children With Chronic Idiopathic Thrombocytopenic Purpura

doi:10.3877/cma.j.issn.1673-5250.2012.05.011

Objective

To investigate immune regulation, clinical efficacy and T lymphocyte subsets of the hoisting soup in the treatment of chronic idiopathic thrombocytopenic purpura (ITP) in children.

Methods

From August 2008 to December 2011, a total of 44 cases with chronic ITP in People's Hospital of Jimo City, Qingdao Municipal Hospital and Taian Chinese Medicine Hospital were included into this study. They were randomly divided into treatment group (n=23) and control group (n=21). Informed consent was obtained from all participates. Treatment group received hoisting soup+ prednison+ adjunctive therapy, control group only received prednisone+ adjunctive therapy. The level of T lymphocyte subsets, platelet and megakaryocyte before and after the treatment were observed.

Results

CD₄⁺ T cell and CD₄⁺ /CD₈⁺ in treatment group increased than those of control group after treating 6 months, but CD₈⁺ T cell in treatment group reduced than that of control group, there had significant difference between two groups (P<0.05). Clinical effects between two groups also had significant difference after the treatment (P<0.05).

Conclusions

Children with chronic ITP presented immunologic functional disorder. Hoisting soup is of immune regulation effect, and reliable curative effects for chronic ITP children.

Key words: hoisting soup, T lymphocyte subsets, idiopathic thrombocytopenic purpura, immune, platelet

表1 治疗组与对照组治疗前、后血小板和骨髓巨核细胞计数比较(±s)

Table 1 Comparison of platelet count and megakaryocyte count before and after the treatment between treatment group and control group (±s)

组别	n	PLT计数(×10⁹/L)				骨髓巨核细胞计数(/4 cm²)
组别	n	治疗前	治疗后1个月	治疗后3个月	治疗后6个月	治疗前	治疗后1个月	治疗后3个月	治疗后6个月
治疗组	23	30.65±18.33	51.35±27.56	82.46±23.49	133.21±61.35	132.58±73.95	73.89±30.12	65.12±11.47	49.87±14.39
对照组	21	29.36±17.28	46.32±23.18	63.16±20.14	67.57±23.82	135.49±69.12	78.62±29.45	74.29±16.39	60.57±17.35
t	?	0.42	0.65	2.91	4.59	0.49	0.53	2.17	2.23
P	?	>0.05	>0.05	<0.05	<0.05	>0.05	>0.05	<0.05	<0.05

表1 治疗组与对照组治疗前、后血小板和骨髓巨核细胞计数比较(±s)

Table 1 Comparison of platelet count and megakaryocyte count before and after the treatment between treatment group and control group (±s)

组别	n	PLT计数(×10⁹/L)				骨髓巨核细胞计数(/4 cm²)
组别	n	治疗前	治疗后1个月	治疗后3个月	治疗后6个月	治疗前	治疗后1个月	治疗后3个月	治疗后6个月
治疗组	23	30.65±18.33	51.35±27.56	82.46±23.49	133.21±61.35	132.58±73.95	73.89±30.12	65.12±11.47	49.87±14.39
对照组	21	29.36±17.28	46.32±23.18	63.16±20.14	67.57±23.82	135.49±69.12	78.62±29.45	74.29±16.39	60.57±17.35
t	?	0.42	0.65	2.91	4.59	0.49	0.53	2.17	2.23
P	?	>0.05	>0.05	<0.05	<0.05	>0.05	>0.05	<0.05	<0.05

表2 治疗组与对照组治疗前、后T淋巴细胞亚群比较(±s)

Table 2 Comparison of T lymphocyte subsets between treatment group and control group(±s)

项目		n	治疗前	治疗后
项目		n	治疗前	1个月	3个月	6个月
CD₄⁺ (%)		?	?	?	?	?
?	治疗组	23	27.74±9.67	29.86±8.53	31.46±7.39	30.18±6.58
?	对照组	21	26.63±9.85	30.58±9.16	33.57±8.12	33.65±7.24
?	t	?	0.32	0.27	0.90	1.67
?	P	?	>0.05	>0.05	>0.05	<0.05
CD₈⁺ (%)		?	?	?	?	?
?	治疗组	23	31.12±12.49	33.69±7.98	35.37±8.76	26.57±7.32
?	对照组	21	30.89±11.76	31.12±9.48	34.19±8.64	34.57±8.11
?	t	?	0.65	0.98	0.45	3.44
?	P	?	>0.05	>0.05	>0.05	<0.05
CD₄⁺/CD₈⁺		?	?	?	?	?
?	治疗组	23	0.86±0.34	0.88±0.46	0.89±0.61	1.14±0.52
?	对照组	21	0.86±0.41	0.97±0.58	0.99±0.73	0.97±0.39
?	t	?	0.25	0.57	0.49	1.22
?	P	?	>0.05	>0.05	>0.05	>0.05

表2 治疗组与对照组治疗前、后T淋巴细胞亚群比较(±s)

Table 2 Comparison of T lymphocyte subsets between treatment group and control group(±s)

项目		n	治疗前	治疗后
项目		n	治疗前	1个月	3个月	6个月
CD₄⁺ (%)		?	?	?	?	?
?	治疗组	23	27.74±9.67	29.86±8.53	31.46±7.39	30.18±6.58
?	对照组	21	26.63±9.85	30.58±9.16	33.57±8.12	33.65±7.24
?	t	?	0.32	0.27	0.90	1.67
?	P	?	>0.05	>0.05	>0.05	<0.05
CD₈⁺ (%)		?	?	?	?	?
?	治疗组	23	31.12±12.49	33.69±7.98	35.37±8.76	26.57±7.32
?	对照组	21	30.89±11.76	31.12±9.48	34.19±8.64	34.57±8.11
?	t	?	0.65	0.98	0.45	3.44
?	P	?	>0.05	>0.05	>0.05	<0.05
CD₄⁺/CD₈⁺		?	?	?	?	?
?	治疗组	23	0.86±0.34	0.88±0.46	0.89±0.61	1.14±0.52
?	对照组	21	0.86±0.41	0.97±0.58	0.99±0.73	0.97±0.39
?	t	?	0.25	0.57	0.49	1.22
?	P	?	>0.05	>0.05	>0.05	>0.05

[1]	Kui LY, Cun SL, Xu J, et al. Analysis of 123 children of idiopathic thrombocytopenic purpura combined with helicobacter pylori infection[J/CD]. Chin J Obstet Gynecol Pediatr:Electron Ed, 2011, 7(2):114-116.
[2]	Zheng QJ, Yu TQ. Clinical observation on therapy of dispelling wind, cooling blood and tonifying kidney for refractory idiopathic thrombocytopenic purpura[J]. Henan Trad Chin Med, 2010, 30(16):580-582.
[3]	Liao QK, ed. Clinical basic of children blood disease. 2nd ed[M]. People's Medical Publishing House, 2001, 693-694.
[4]	Liu M, Song MF, Zhao WJ, et al. The clinical study of"Rise blood number Ⅱ"on the treatment of chronic ITP:36 cases report[J]. Sichuan Trad Chin Med, 2008, 26(11):65-66.
[5]	Xiao H, Liu F, Wu CL, et al. Study on the expression of apoptotic related proteins on T cell subsets and thrombocyte in idiopathic thrombocytopenic purpura children[J]. J Clin Hematol, 2007, 20(5):275-277.
[6]	Ou GS. Detection of apoptosis-related proteins on T cell subsets and thrombocyte in acute idiopathic thrombocytopenic purpura[J]. J Xianning Coll:Med Sci, 2005, 19(6):487-489.
[7]	Fan Y, Ma J, Tao SC. Effects of Zidian granules on the levels of IL-2, IL-6 and IL-8 in the peripheral blood of the mouse model of idiopathic thrombocytopenic purpura[J]. Chin J Exp Trad Med Formulae, 2005, 11(4):39-41.
[8]	Xiao H, Liu F, Wu CL, et al. The analysis of peripheral blood T cell subgroup in children ITP[J]. J Exp Hematol, 2006, 14(4):722-725.

[1]	Chun Yi, Dongsheng Yuan, Xuejun Xiong. Relationship of systemic immune-inflammation index with decreased bone mass density and osteoporosis[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(05): 609-617.
[2]	Yalong Li, Xingtong Wang, Chuan'an Shen. Clinical advances in the application of allogeneic platelet-rich plasma in wound healing[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(06): 541-545.
[3]	Zhenyu Wang, Hongmei Zhang, Lin Jing, Mingjiang He, Qi Yan. Causal relationship and mediating effect between knee osteoarthritis related inflammatory factors and plasma metabolites[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(06): 467-473.
[4]	Huan Liu, Hao Xing, Zhengqi Chang, Ji Zhang. Research progress on mechanosensitive ion channel protein Piezo1 in infection-related diseases[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(05): 263-269.
[5]	Ke Ding, Yaqiong Zhang, Jie Liu, Liping Deng, Yongxi Zhang, Yong Xiong. Clinical characteristics and trends in survival status of patients with acquired immunodeficiency syndrome-related lymphoma[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(05): 278-284.
[6]	Jie Zhang, Xiaoxia Luo, Hong Yu. Predictive value of systemic immune inflammation index in patients with acute pancreatitis complicated with organ function impairment[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 68-71.
[7]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[8]	Dawei Wang, Yafei Lu, Shaohua Huangfu, Yuting Chen, Ao Chen, Bin Jiang. Advances in immune modulating mechanisms of mesenchymal stem cells in promoting wound healing[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(06): 361-366.
[9]	Jie Mei, Rui Xu, Yun Cai, Yichao Zhu. The effects of fibrosis on tumor-infiltrating immune cells——the formation of "armored & cold tumors"[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(05): 257-263.
[10]	Weijie Chen, Xiaodong He. Progress in immunotargeted therapy for gallbladder cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 763-768.
[11]	Minsi Liu, Rong Li, Mei Li. Diagnostic value of GGT-Plt ratio-based model for HBV-related hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 831-835.
[12]	Long Zhang, Shanke Sun, Wei Xu, Wenzhu Li, Junda Li, Yongquan Chi, Guangsheng He, Feng Cheng, Xuehao Wang, Jianhua Rao. Clinical efficacy of laparoscopic splenectomy in the treatment of hematological diseases[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 870-875.
[13]	Huiling He, Zubin Lu, Jiali Feng, Shengqiang Liang. Effect of preoperative peripheral blood NLR and PLR on postoperative colon cancer liver metastasis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 682-687.
[14]	Tianfu Wang, Gang Wang. Diagnosis and treatment of autoimmune pancreatitis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 492-497.
[15]	Jian Cui, Qing Xia, Yun Lin, Guangling Li, Xinna Li, Wei Wang. Effects of platelet to lymphocyte ratio, immunoglobulin, myocardial enzyme spectrum and electrocardiogram parameters on the condition and prognosis of middle-aged and elderly patients with cirrhosis[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 400-406.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export